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Abstract
Objective: Numerous acquired etiological factors, such as infections, malignancies, and collagen tissue 
disorders, are involved in the development of acquired hemophagocytic lymphohistiocytosis (AHLH). 
Not everyone with the same etiological factors developments AHLH, which suggests the role of addi-
tional genetic or environmental predisposing factors that remain to be identified. 
Materials and Methods: Perforin gene A91V missense transition (C>T change at position 272 in exon 
2 of the perforin gene) and TNF-α gene promoter-1031 T>C nucleotide substitution are 2 candidate 
genetic predisposing factors due to their potential to alter inflammatory responses. In the present 
study these changes were investigated in healthy controls and AHLH patients.
Results: A91V transition was observed in 7 of the 159 (4.4%) controls. Among the 44 AHLH patients, 
5 (11.3%) were heterozygous and the difference in the frequency of A91V transition, although striking 
(odds ratio: 2.8), was not statistically significant (p=0.09). All A91V-positive patients had infection. 
TNF-α-1031 T>C polymorphism was examined in 164 healthy controls and 40 AHLH patients, and 
the CC risk-elevating genotype was noted in 7 (4.3%) of the controls and 1 (2.5%) of the AHLH 
patients. The frequency of C and T alleles was 22.5% (n=18) and 77.5% (n=62) among the AHLH 
patients, and 22% (n=72) and 78% (n=259) among the controls, respectively. There wasn’t a statisti-
cally significant difference between the groups in terms of allele frequencies (p>0.05).
Conclusion: The present results indicate that compared to controls, A91V mutation was 2.8-fold more 
prevalent (according to the odds ratio) in the AHLH patients. A91V mutation is not uncommon in the 
general population and increases the risk of AHLH in patients with an underlying condition, espe-
cially those with an underlying infection. (Turk J Hematol 2011; 28: 125-30)
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Hemophagocytosis is a mysterious abnormal cel-
lular condition that accompanies several disorders. 
One such disorder is genetically transmitted familial 
(primary)  hemophagocytic  lymphohistiocytosis 
(HLH), which is characterized by high fever, hepato-
splenomegaly, cytopenia, hyperferritinemia, hypertri-
glyceridemia  and/or  hypofibrinogenemia,  a  high 
level  of  the  alpha  chain  of  soluble  interleukin-2 
(sCD25),  low  natural  killer  (NK)  cell  activity,  and 
hemophagocytosis  in  bone  marrow,  cerebrospinal 
fluid (CSF), or lymph nodes [1]. Mutations in 4 differ-
ent genes, namely perforin on chromosome 10q21, 
munc 13-4 on 17q25, syntaxin 11 on 6q24, and syn-
taxin-binding  protein  2  (STXBP2)  on  19p13.2  are 
reported to be responsible for familial HLH [2-5].
Another  hemophagocytosis-related  disorder  is 
acquired (secondary) HLH (AHLH), which is related 
to all of the above criteria of the Histiocyte Society, 
except for a genetic defect in 1 of the familial HLH-
associated  genes.  AHLH  is  commonly  associated 
with  various  etiologic  agents,  such  as  infectious 
agents-particularly viruses-malignancy, and autoim-
mune diseases such as juvenile rheumatoid arthritis 
[6-9]; however, why some patients with an underly-
ing disorder develop AHLH and others don’t in the 
presence of the same etiological factor is not known 
and requires further investigation.
 Recently, 272C>T nucleotide changes in exon 2 
of  the  perforin  gene,  which  leads  to  alanine  91 
valine (A91V) amino acid substitution, was described 
as a polymorphism because of its high incidence 
rate, which varies from 3% to 17% in healthy popula-
tions  [10,11].  Subsequently,  it  was  reported  that 
A91V causes conformational changes and impairs 
the process by which perforin protein becomes the 
active form [12,13]. A91V is reported to be associ-
ated with mutations in the perforin and munc 13-4 
genes [14]. In addition, it was suggested that homo-
zygous  A91V  transition  is  a  cause  of  infection-
induced  FHL,  and  it  was  also  suggested  that  the 
transition is a predisposing factor in such disorders 
as  autoimmune  lymphoproliferative  syndrome-a 
childhood acute lymphoblastic leukemia-and type 1 
diabetes [15-19]. As such, it is very likely that A91V 
plays a role in the pathogenesis of AHLH by reduc-
ing the cytotoxicity of cytotoxic T lymphocytes and 
NK cells [11-13]. 
 On the other hand, it was reported that a num-
ber of cytokines are elevated in HLH, such as tumor 
necrosis  factor  (TNF)-α,  interferon  (IFN)-γ,  and 
interleukin  (IL)-6,  IL-10,  IL-12,  IL-16,  and  IL-18. 
Hypercytokinemia results from uncontrolled activa-
Özet
Amaç: Edinsel hemofagositik lenfohistiositozun (EHL) gelişmesinde enfeksiyonlar, habis hastalıklar, 
kollajen doku hastalıkları gibi çok çeşitli etmen rol oynamaktadır. Aynı tetikleyici faktörü bulunan 
hastaların tümünde EHL’un gelişmemesi EHL’ye yatkınlık yapan ek genetik ve çevresel faktörlerin 
varlığına işaret etmektedir. 
Yöntem ve Gereçler: Perforin geninde A91V yanlış anlam değişikliği (perforin geninde ekzon 2, pozisyon 
272’de C>T değişikliği) ve tumor nekrozis faktör (TNF)-α geninin promoter bölgesinde –1031T>C 
nükleotid değişikliği inflamatuvar yanıtı değiştirebilen ve bu nedenle EHL’ye yatkınlığa neden olabilen iki 
potansiyel adaydır. Çalışmamızda EHL’li hastalar ve kontrollerde bu değişiklikler incelenmiştir. 
Bulgular: 159 sağlıklı Türk popülasyonunda A91V değişikliği 7 (%4.4) kişide saptanmıştır. 44 EHL 
olgusunun beşinde (%11.3) bu değişiklik saptanmış olup, fark dikkat çekici olmakla birlikte istatistik-
sel  anlamlılık  göstermemiştir  (p=0.09);  odds  oranı  2.8  olarak  hesaplanmıştır.  A91V  pozitif  olan 
hastaların  tümünde  enfeksiyon  altta  yatan  etiolojik  nedendi.  TNF-α  -1031T>C  polimorfizmi  164 
sağlıklı birey ve 40 EHL’li hastada çalışıldı. Kontrollerin 7’sinde (%4.3) ve EHL bulunan hastaların 
1’inde (%2.5) riski artıran CC genotipi saptandı. C ve T allel frekansları sırasıyla EHL’de 18 (%22.5) 
ve 62 (%77.5), kontrollerde 72 (%22) ve 259 (%78) olarak bulundu. Allel frekansları açısından grup-
lar arasında fark saptanmadı (p>0.05). 
Sonuçlar: Çalışmamızın sonuçları edinsel HLH’li hastalarda sağlıklı kontrollara göre A91V sıklığının 
2.8 kat odds oranına göre daha sık olduğunu, A91V’nin sağlıklı Türk populasyonunda nadir olmadığını 
ve özellikle enfeksiyonu olanlarda EHL’ye yatkınlık yapabileceğini göstermektedir. 
 (Turk J Hematol 2011; 28: 125-30)
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ratory findings of HLH were reported to be due to 
organ infiltration by histiocytes and lymphocytes, as 
well as hypercytokinemia. Among these cytokines, 
TNF-α is a major cytokine that plays a critical role in 
the pathogenesis of inflammatory, malignant, and 
autoimmune disorders. The C allele of -1031 T>C 
polymorphism  in  the  TNF-α  gene  promoter  was 
reported  to  increase  susceptibility  to  AHLH  in  a 
Korean population [20]. 
 AHLH is relatively common in Turkey, but not 
much is known about its predisposing factors [6-9]. 
The present study aimed to investigate the frequen-
cy of the A91V mutation in healthy controls and to 
determine the roles of A91V and TNF-α-1031 T>C 
changes in the pathogenesis of AHLH.
Materials and Methods
Patients and controls
The study included 44 unrelated AHLH patients 
treated at 2 hospitals (42 from Hacettepe University 
and 2 from Kırıkkale University) between 2005 and 
2009, and 164 healthy controls. The controls were 
blood bank donor samples that were used following 
receipt of written informed consent by the donors. 
Among  the  patients,  44  (32M/12)  fulfilled  the 
Histiocyte Society diagnostic criteria for AHLH. The 
patients ranged in age from 1 d to 16 years (median 
age: 2 years). The study protocol was approved by 
the Hacettepe University Ethics Committee (approv-
al  number:  TBK  05/19-25)  and  written  informed 
consent was obtained from all the participants. 
Genotyping
Genomic DNA was isolated from EDTA-preserved 
peripheral venous blood cells using automatic isola-
tion  methods  (MagnaPure  Large  Volume  Nucleic 
Asit  Isolation  Kit,  Roche).  Individuals  were  geno-
typed  for  A91V  transition  using  custom-designed 
probes  for  the  LightCyclerTM  instrument  (Roche 
Applied  Sciences,  Mannheim,  Germany),  and  for 
the TNF-α-1031.
T>C polymorphism using the 5’ nuclease poly-
merase  chain  reaction  (TIBMOLBIOL,  Germany),   
as  previously  described  [21].  Statistical  analyses 
were performed using Fisher’s exact and chi-square 
tests.
Results
The  etiologic  agents  in  the  AHLH  patients  are 
shown in Table 1. In all, 3 patients had skin eruption, 
fever, and lymphocyte predominance in peripheral 
blood.  These  patients  were  accepted  as  having 
unknown  viral  infections.  There  was  first-degree 
consanguinity between the parents of 15 patients 
and the parents of 3 other patients were from the 
same  village,  suggesting  possible  consanguinity; 
therefore,  the  families  were  further  analyzed  via 
haplotype  analysis  for  HLH  mutations,  including 
perforin,  munc  13-4,  and  syntaxin  11  genes,  and 
none had haplotype homozygosity for these genes. 
A91V status of the patients 
Among  the  159  healthy  controls,  7  (4.4%)  had 
A91V transition (Table 2). The controls that had the 
Table  1.  Etiologic  agents  and  perforin  A91V  transition  in  the 
AHLH patients
Underlying Disease  Number of   A91V mutation
  Patients  positive
EBV infection  6  2
Leukemia  5 
Autoimmune disease  4 
Combined E. coli and   3  1
Pseudomonas aeruginosa sepsis 
Pneumonia  3  1
Respiratory tract infection  3 
Sepsis (Streptococcus viridians)  1 
MAS  2 
CMV  2 
HHV-6  1 
Parvovirus B19  1 
Brucella  1 
Salmonella  1 
Unknown-possible viral infection  3  1
Metabolic disorder*  3 
Hepatitis of unknown origin  1 
Inflammatory bowel disease  1 
Langerhans cell histiocytosis  1 
Myelodysplastic syndrome  1 
Neonatal hemochromatosis  1 
EBV: Epstein-Barr virus; MAS: macrophage activation syndrome; HHV-6: human 
herpes virus 6; CMV: cytomegalovirus; JMML: juvenile myelomonocytic leukemia
*The underlying metabolic disorders were glycogen storage disease, Gaucher 
disease, and propionic acidemia
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disease at the time the results were obtained. In all, 
5 (11.3%) of the AHLH patients were heterozygous 
for the A91V transition (Table 2). The difference in 
the frequency of the transition between the AHLH 
and control groups was not statistically significant 
(Fisher’s exact test, p=0.090), although it was strik-
ingly  higher  in  the  AHLH  group  (odds  ratio:  2.8). 
Among the 5 patients with A91V, 2 had infectious 
mononucleosis, 1 had Escherichia coli and P. aeru-
ginosa sepsis, 1 had pneumonia, and 1 had a viral 
infection of unknown origin (Table 1). 
TNFα promoter-1031 T>C polymorphism
TNF-α-1031  T>C  polymorphism  findings  are 
given in Table 2. Among the 164 controls, 7 (4.3%) 
had homozygous risk of elevated CC and 58 (35.4%) 
had  heterozygous  TC  genotypes.  Among  the  40 
AHLH patients examined for the polymorphism, 1 
(4%) had the CC genotype and 16 (40%) had the TC 
genotype. Among the 164 controls that were ana-
lyzed for TNF polymorphisms and the 40 patients 
whose DNA was available for analysis, there wasn’t 
a statistically significant difference between allele 
status (p=0.78). The frequency of C and T alleles 
was  22.5%  (n=18)  and  77.5%  (n=62)  among  the 
AHLH patients, and 22% (n=72) and 78% (n=259) 
among  the  controls,  respectively.  There  wasn’t  a 
statistically significant difference between groups in 
terms of T and C allele frequencies (p>0.05). 
Discussion
The  present  study  obtained  initial  data  on  the 
frequency of A91V in Turkey (4.4%), indicating that 
it was quite common in the controls, as previously 
reported  [10,15].  In  the  present  study  5  (11.3%) 
AHLH patients with infection had A91V in the het-
erozygote state, suggesting that the transition may 
be  a  predisposing  factor  for  infection-associated 
AHLH; the difference between the 2 groups was not 
statistically significant. Nonetheless, the difference 
between the AHLH patients and healthy controls in 
terms of A91V status was striking (odds ratio: 2.8); 
this problem might be overcome by increasing the 
number of participants in future studies. Among the 
5 patients that had A91V, 2 had severe EBV infection, 
1 had neonatal sepsis due to E. coli and P. aerugi-
nosa, 1 had severe pneumonia, and 1 had a proba-
ble  viral  infection  of  unknown  origin,  which  may 
indicate the additive effect of carrier state and infec-
tions in the development of HLH. Although the num-
ber of patients in the present study was small, the 
statistically non-significant but higher rate of A91V in 
the  AHLH  patients  suggests  that  especially  in  the 
presence  of  infection  as  a  triggering  factor  A91V 
transition may play a predisposing role in the emer-
gence of full-blown AHLH. Additionally, the present 
results would have been more useful had perforin 
expression  analysis  been  performed  in  all  of  the 
patients and controls. 
TNF-α promoter-1031 T>C polymorphism, which 
is reported to have a significant affect on transcrip-
tion, was not observed to increase the risk of AHLH 
in the present study. A study on patients with AHLH 
reported that this cytokine polymorphism and the 
TNFα-1031 C allele increased the risk of AHLH [19]. 
Discrepancies  between  the  reported  results  may   
be due to differences in the genetic pools of the 
study  populations  included  in  these  2  studies. 
Additional research with different populations and 
larger  patient  cohorts  will  help  in  elucidating  the 
contribution of this polymorphism to the develop-
ment of AHLH. 
In conclusion, the prevalence of A91V was rela-
tively high in the present study. The rate of A91V 
transition was 4.4% among the controls and 11.3% 
among the AHLH patients; the difference was not 
statistically  significant,  but  the  incidence  of  A91V 
transition  was  approximately  3-fold  higher  in  the 
patients according to the odds ratio. TNF-α polymor-
phisms did not contribute to AHLH according to the 
present findings. The presence of A91V might con-
tribute to the development of AHLH, especially in 
Table 2. Distribution of perforin gene A91V transition, and TNF-α promoter-1031 T>C polymorphism genotypes and alleles
Group  Perforin A91V       TNF-α-1031 T>C 
          Genotype    Allele
  Total Studied  A91V+  Total Studied  CC  TC  TT  C  T
  (n)  n (%)  (n)  n (%)  n (%)  n (%)  n (%)  n (%)
AHLH  44  5 (11.3)  40  1 (2.5)  16 (40)  23 (57.5)  18 (22.5)  62 (77.5)
Control  159  7 (4.4)  164  7 (4.3)  58 (35.4)  99 (60.3)  72 (22)  256 (78)
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therefore,  A91V  transition  should  be  screened  in 
patients-particularly  those  with  infection-induced 
AHLH-to ensure that patients are closely monitored. 
Additional research with larger AHLH patient groups 
is needed to more clearly delineate the role of A91V 
transition in AHLH.
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